Complejo Hospitalario de Navarra

Navarro 31008

0 studies enrolling now · 3 studies all time

What they study most

Estrogen Receptor Positive Breast Cancer, Follicular Lymphoma (FL), HER-2 Positive Breast Cancer, HER2-Positive Primary Breast Cancer, Marginal Zone Lymphoma, Non Hodgkin Lymphoma, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer — Running, not enrolling
• Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) — Stopped early